As we said in our editorial released in the wake of the news of Pfizer-BioNTech’s new vaccine six days ago , the announcement is obviously excellent news and we are not going back on that. Nevertheless, we need to look at the uncertainties liable to shape decision-makers’ and investors’ expectations over the next few months.